Jason Lettmann joined Morgenthaler in 2009 and is a Partner on the Life Science Team. Jason is based in Palo Alto, CA, and invests in the life science and medical device sectors. He currently serves on the Board of Directors of FIRE1, Relievant Medsystems, Second Genome and Vapotherm. He was a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013. At Morgenthaler, Jason was also a Board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014).
Before joining Morgenthaler, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical, EBR Systems, Evalve (acquired by Abbott Labs) and Miramar Labs, as well as with the founding of Zyga Technologies.
Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture and business development as well as a consultant with Accenture’s Health and Life Science practice where he advised clients across the medical device, pharmaceutical and health payer sectors. Jason also previously worked as a genetic research analyst at the University of Iowa Hospitals and Clinics.
Jason holds an M.B.A. with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.
- Relievant Medsystems
- Second Genome
- Tarsus Medical
Life Sciences/Medical Devices
- The Human Microbiome Gets A Big Pharma Investment
- Second Genome Closes Series A With $11.5M
- Vapotherm Closes $29 Mln Round
- Relievant Medsystems Announces $30 Million Series D Financing
- Relievant Medsystems Receives FDA Approval to Begin Pivotal Study
- Second Genome Raises $5M Series A To Map Microbes
- Second Genome Announces Series A Financing